Nicolas Chouin

5PUBLICATIONS
17CO-AUTHORS
Molecular targetsGene and molecular therapyPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jul 29, 2023
Preclinical Evaluation of a 64Cu-Based Theranostic Approach in a Murine Model of Multiple Myeloma.

Cassandra Métivier, Patricia Le Saëc, Joëlle Gaschet

|Jun 14, 2023
From bench to bedside: 64Cu/177Lu 1C1m-Fc anti TEM-1: mice-to-human dosimetry extrapolations for future theranostic applications.

Silvano Gnesin, Nicolas Chouin, Michel Cherel

|Apr 03, 2021
Anti-Tumor Efficacy of PD-L1 Targeted Alpha-Particle Therapy in a Human Melanoma Xenograft Model.

Marisa Capitao, Justine Perrin, Sylvain Simon

|Sep 25, 2020
Targeted-Alpha-Therapy Combining Astatine-211 and anti-CD138 Antibody in A Preclinical Syngeneic Mouse Model of Multiple Myeloma Minimal Residual Disease.

Sébastien Gouard, Catherine Maurel, Séverine Marionneau-Lambot

|May 30, 2019
What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between 89Zr- and 64Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model.

Clément Bailly, Sébastien Gouard, François Guérard

Pageof 1

Frequent Collaborators

4 joint publications

Michel Chérel

2 joint publications

Clément Bailly

2 joint publications

Raphaël Tripier

2 joint publications

Ferid Haddad